Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Coated Stent Launch Expected In All International Markets By May 20

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson must provide regular updates on the long-term performance of its Cypher drug-eluting coronary stent to the British Standards Institution (BSI) following CE mark approval April 12. No postmarket study is required

You may also be interested in...



Preliminary Data From J&J SIRIUS Coated Stent Trial Consistent With RAVEL

Data from the first 400 patients in Johnson & Johnson's U.S. SIRIUS trial of the Cypher sirolimus-eluting coronary stent appear consistent with positive European data from the RAVEL trial, despite inclusion of a larger and sicker patient cohort

Preliminary Data From J&J SIRIUS Coated Stent Trial Consistent With RAVEL

Data from the first 400 patients in Johnson & Johnson's U.S. SIRIUS trial of the Cypher sirolimus-eluting coronary stent appear consistent with positive European data from the RAVEL trial, despite inclusion of a larger and sicker patient cohort

J&J Cypher Royalties To Drive SurModics Projected Growth Of 20-25% In 2002

Royalties from Johnson & Johnson/Cordis' Cypher drug-eluting stent sales are expected to drive SurModics' fiscal 2002 top line growth "in the 20 to 25% range," SurModics says

Related Content

UsernamePublicRestriction

Register

MT016443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel